This document addresses the European Union regulatory position in the main topics of clinical development of new medicinal products in the treatment of irritable bowel syndrome.
Keywords: Irritable bowel syndrome, Rome criteria, patient reported outcome (PRO), health related quality of life (HrQoL)
Current effective version
Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1
This guideline intends to address the EU regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with Irritable Bowel Syndrome (IBS).
English (EN) (230.59 KB - PDF)
Document history
Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1
This guideline intends to address the EU regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with Irritable Bowel Syndrome (IBS).
English (EN) (230.59 KB - PDF)
Overview of comments received on guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome (CPMP/EWP/785/97 Rev. 1)
Overview of comments received on Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome' (CPMP/EWP/785/97 Rev. 1)
English (EN) (213.71 KB - PDF)
Draft guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1
This guideline intends to address the European Union regulatory position in the main topics of clinical development of new medicinal products in the treatment of patients with irritable bowel syndrome.
English (EN) (200.82 KB - PDF)
Concept paper on the revision of the CHMP points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome
The proposed guideline will replace 'points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97'. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.
English (EN) (73.55 KB - PDF)
Points to consider on the evaluation of medicinal products for the treatment of Irritable Bowel Syndrome
English (EN) (175.02 KB - PDF)
Related content
- Clinical efficacy and safety: alimentary tract and metabolism
- Directive 2001/83/EC
- Conduct of pharmacovigilance for medicines used by the paediatric population
- Extrapolation of results from clinical studies conducted outside Europe to the EU-population
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E10 Choice of control group in clinical trials
- Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products